Table 2: Comparison of ocular findings of patients treated with high-dose, moderate-dose, and low-dose infliximab at baseline examination and at one-year followup.

ACDFlareVisual acuityIOP
PatientBaseline12 monthBaseline12 monthBaseline12 monthBaseline12 month
OSODOSODOSODOSODOSODOSODOSODOSOD

HD12+2+003+1+1+0HM8ft/200HM1ft/200HHHN
23+01+03+2+1+0HM20/20HM20/20HNHN
32+2+2+1+1+1+1+020/6020/3020/10020/60HHNN
42+2+1+1+3+2+0020/80020/80020/2020/70HHNN
52+2+0001+0020/40020/2020/2020/20HNHN
62+2+2+2+3+3+1+1+20/1255ft/40020/125HMNHNH
72+1+001+2+00LP20/200LP20/80HNHN
83+3+003+3+0020/40020/20020/4020/40HHNN
91+2+2+2+2+2+1+1+20/30020/4020/20020/100HNNN

MD102+2+002+2+0020/6020/4020/4020/40NNNN
111+1+002+1+0020/40020/3020/5020/20HNHN
121+1+001+1+0020/3020/4020/3020/30NHNN
133+2+1+1+2+2+1+1+20/2520/2520/2020/20HNNN
141+1+002+2+0020/2520/2520/2020/25HNNN
152+2+001+1+0020/3020/3020/2020/20NNNN
162+2+2+1+2+3+0020/2520/4020/2020/60HNNN
172+2+1+1+1+1+0020/10020/2020/6020/20NNNN
182+2+1+1+2+2+01+20/10020/20020/6020/400NNNH
192+2+1+1+1+1+0020/20020/20020/20020/200NNNN
201+1+1+1+1+1+0020/80LP20/40LPNHNH
212+2+002+3+0020/2020/40020/4020/200NNNN
222+2+002+2+0020/20020/20020/4020/40HNNN
233+3+002+2+0020/2020/4020/2020/20NNNN
24NA2+NA001+0020/4020/20020/4020/40NNNN
251+1+002+1+0020/6020/4020/2020/20NNNN
262+2+002+2+0020/2020/4020/2020/20NNNN
271+1+002+2+0020/8020/2020/6020/20NNNN
282+2+001+1+01+20/2020/2020/2020/20NNNN

LD292+1+003+2+0020/10020/2020/2020/20NNNN
301+1+0001+0020/2020/8020/2020/30NNNN
312+2+002+2+0020/4020/3020/8020/30NNNN
322+1+001+1+0020/2020/2020/2020/20NNNN
331+2+001+2+0020/2020/2020/2020/20NNNN
341+2+001+2+0020/2020/2020/2020/20NNNN

HD-high dose; MD-moderate dose; LD-low dose; ACD-anterior chamber cell density; IOP-intraocular pressure; LP-light perception; HM-hand movement; N-normal; H-high; Ft-feet; OS-ocular sinister; OD-oculus dexter.